A study on prescription pattern of statins in cardiovascular disease

Der Pharmacia Lettre

Volumn 3, Issue 3, 2011, Pages 393-396

  Sreedevi, K ^a   Venkateswara Rao, J ^a   Fareedullah, Md ^b   Vijayakumar, S ^b  

^a SULTAN UL ULOOM COLLEGE OF PHARMACY   (India)

^b Vaagdevi College of Pharmacy   (India)

Author keywords

Cardiovascular disease; Cholesterol; Secondary prevention; Statins

Indexed keywords

ATORVASTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; FEMALE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OSTEOPOROSIS; POLYPHARMACY; PRESCRIPTION; PRIMARY PREVENTION; RISK REDUCTION; SECONDARY PREVENTION; SEX DIFFERENCE; THYROID DISEASE;

EID: 79961036342     PISSN: None     EISSN: 09755071     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. th edition 1985; 154-1594.
2. The rational use of drugs: report of the conference of experts. Nairobi, 25-29 November 1985. Geneva, world health organization, 1987.
3. Edward J. Mills, Beth Rachlis, Ping Wu, Philip J. Devereaux, Paul Arora, Dan Perri. Journal of the American College of Cardiology. 2008; 52(22):1769-81.
4. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G. Science. 1999; 286 (5446):1946-9.
5. Wolozin, B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. BMC Medicine. 2007; 5:20.
6. Klein BE, Klein R, Lee KE, Grady LM., JAMA. 2006; 295(23):2752-8.
7. Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH. Arch. Intern. Med. 2008; 168(7):721-7.
8. Khurana V, Bejjanki HR, Caldito G, Owens MW. Chest. 2007; 131(5):1282-8.
9. Mondul AM, Han M, Humphreys EB, Meinhold CL, Walsh PC, Platz EA. Journal of Urology. 2011; 185(4):1268-73.
10. Bimo, Chowdhary A, Das A, Diwan V, Kafle KK, Mabadeje B, et al. In: How to investigate drug use in health facilities (selected drug use indicator) action programme on essential drugs. WHO official publication, 1995:68.
11. Victora CG, Facchini LA, Grassi Filho M. Trop Doct. 1982; 12:231-5.
12. Bosu WK, Ofori-Adjei D. A Trop Doct. 1997; 4:222-6.
13. Hazra A, Tripathi SK, Alam MS. Natl Med J India. 2000; 13(4):177-82.
14. Flaherty JH, Perry HM 3rd, Lynchard GS, Morley JE. J Gerontol A Biol Sci Med Sci. 2000; 55(10):M554-9.
15. Scandinavian Simvastatin Survival Study Group. Lancet. 1994; 344:1383-9.
16. 2. Sacks FM, Pfeffer MA, Moye LA, N Engl J Med. 1996; 335:1001-9.
17. Ong HT. PLoS Med. 2006; 3:e50.
18. Ma J, Sehgal NL, Ayanian JZ, Stafford RS. PLoS Med. 2005; 2:e123.
19. IMS Institute for Healthcare Informatics: "The Use of Medicines in the United States: Review of 2010," April 2011. Available online at http://blog.targethealth.com/?m=201104.